Bart D. T.
- Country
- Belgium
- Department
- Urology
Research Overview
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
- Phase 3 Randomized Trial of Intravesical Erdafitinib Delivery System vs. Single-Agent Chemotherapy in FGFR+ Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Efficacy and Safety Evaluation of TAR-200 and Cetrelimab in High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
Data & Insights
Has run more than one trial at 38 of 141 partner sites.
Specializations
Bladder Cancer Research
This investigator specializes in the treatment of various forms of non-muscle invasive bladder cancer (NMIBC), with particular emphasis on innovative therapeutic approaches for high-risk cases.
- High-risk NMIBC management
- FGFR-positive bladder cancer treatment
- Intravesical therapy development
The research focuses on novel therapeutic combinations and alternative treatments for patients unresponsive to conventional therapies.
Urological Oncology
The investigator conducts research in advanced therapeutic strategies for urological malignancies, including both bladder and prostate cancer treatments.
- Targeted therapy approaches
- Combination treatment strategies
- Novel therapeutic agents
Their work encompasses both early-stage and advanced urological cancers, focusing on personalized treatment approaches.
Prostate Cancer Innovation
The investigator explores cutting-edge approaches in high-risk prostate cancer treatment, incorporating advanced diagnostic and therapeutic methodologies.
- Molecular imaging applications
- Treatment intensification strategies
- Quality of life optimization
Research includes novel diagnostic tracers and therapeutic combinations for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.